KMDA: kamada.com Expected earnings per share growth for next year

Public company logo of Kamada Ltd. (KMDA)

Despite pressure from global players and raw material shortage risks, stringent FDA requirements and patent protection create an insurmountable barrier for new entrants. The consensus forward EPS growth forecast helps balance these factors, where the value of 19.70 corresponds to the current metric. Consequently, Kamada Ltd. (KMDA) maintains its leadership in the B2B rare disease segment thanks to unique antibodies.

Kamada Ltd (KMDA): Net earnings per share change forecast for next year from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company kamada.com (KMDA)

- share price and consensus valuation forecast:
Stock Price Kamada Corp|KMDA - Broker Consensus Forecast
- market capitalization information:
Market Valuation Kamada|KMDA - Value Adjusted for Debt and Cash
- book capitalization information:
Net Assets per Single Share Kamada|KMDA - Net Asset Value|Market Capitalization to Book Value Ratio kamada.com|KMDA - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Capital Kamada Ltd.|KMDA - Long-Term Debt to Capital|Short-Term Debt to Equity Kamada|KMDA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Kamada|KMDA - Company Long-Term Liabilities|Company Short-Term Debts Kamada|Quick Liquidity kamada.com
- net income and valuation ratios data:
KMDA - Net Profit|Projected Future Earnings Kamada Ltd.|KMDA - P/E Multiple|Future Price to Earnings Kamada Ltd.|KMDA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Kamada|KMDA - Operating profit EBITDA|Net earnings per share (EPS TTM) Kamada|KMDA - Earnings per share for the last 12 months|Quarterly EPS earnings growth kamada.com|KMDA - Earnings growth in current year|Expected earnings per share growth for next year Kamada Ltd.
- sales revenue and business income indicators:
KMDA - Company Sales Revenue|Company Projected Revenue Kamada Corp|KMDA - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Kamada
Fundamental company valuation:KMDA, Kamada Corp
Finished products of Kamada

The resilience of Kamada Ltd. (KMDA) is based on the non-cyclical demand for plasma-derived therapies and the stability of government contracts. This metric aggregates expert consensus forecasts for earnings per share (EPS) changes, reflecting market yield expectations. By analyzing the current valuation of the company's EPS growth for the coming year, an investor determines the probability of earnings deviating from the norm. These data allow for the adjustment of the asset's fair value based on future cash flows.

Analysis of competing companies

VRTX (Vertex Pharmaceuticals Inc.) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year ALNY (Alnylam Corp)|Expected earnings per share growth for next year INSM (Insmed Incorporated)|UTHR (unither.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year BioMarin BMRN|BBIO (BridgeBio Pharma) - Net earnings per share change forecast for next year|BGM Group Corp - Earnings growth forecast for next year|Expected earnings per share trend next year COGT (Cogent Corp)|XERS: Earnings growth forecast for next year|kerostx.com (KROS) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Arcturus Therapeutics Holdings Inc.|ETON: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Fulcrum Tx (FULC)|Expected earnings per share growth for next year abeonatherapeutics.com ABEO|Earnings growth forecast for next year MREO (Mereo BioPharma Group plc)|Earnings growth forecast for next year protalix.com PLX|PLRX - Net earnings per share growth forecast for next year|APLT - Earnings growth forecast for next year|RNTX: Earnings growth forecast for next year|Gelteq (GELS) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Aytu BioPharma Inc|Expected earnings per share growth for next year Chemomab (CMMB)|Earnings growth forecast for next year SRXH|Earnings growth forecast for next year polyrizon-biotech.com (PLRZ)|Earnings growth forecast for next year AEZS (Aeterna Zentaris Inc.)|CYTH: Projected earnings per share growth rate for next year|Inozyme - Earnings growth forecast for next year|RPHM - Earnings growth forecast for next year|CSCI (COSCIENS Biopharma) - Expected earnings per share growth for next year